MIRA Pharmaceuticals, Inc. (MIRA)
(Delayed Data from NSDQ)
$5.01 USD
+4.32 (627.35%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $3.96 -1.05 (-20.96%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for MIRA Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | NA | NA | NA |
Cost Of Goods | 0 | 0 | NA | NA | NA |
Gross Profit | 0 | 0 | NA | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 9 | 7 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -7 | 0 | 0 | 0 |
Non-Operating Income | 0 | 0 | NA | NA | NA |
Interest Expense | 3 | 0 | NA | NA | NA |
Pretax Income | -12 | -7 | NA | NA | NA |
Income Taxes | 0 | 0 | NA | NA | NA |
Minority Interest | 0 | 0 | NA | NA | NA |
Investment Gains/Losses | 0 | 0 | NA | NA | NA |
Other Income/Charges | 0 | 0 | NA | NA | NA |
Income From Cont. Operations | -12 | -7 | NA | NA | NA |
Extras & Discontinued Operations | 0 | 0 | NA | NA | NA |
Net Income (GAAP) | -12 | -7 | NA | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -7 | 0 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | NA | NA | NA |
Income After Depreciation & Amortization | -9 | -7 | 0 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.57 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.64 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.64 | NA | NA | NA | NA |
Fiscal Year end for MIRA Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.77 | 2.61 | 3.16 | 0.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.77 | -2.61 | -3.16 | -0.97 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | -0.05 | 2.73 | 0.43 | 0.30 |
Pretax Income | NA | -1.72 | -5.79 | -3.59 | -1.27 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.72 | -5.79 | -3.59 | -1.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.72 | -5.79 | -3.59 | -1.27 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 19.71 | 18.57 | 13.64 | 13.31 |
Diluted EPS Before Non-Recurring Items | NA | -0.12 | -0.19 | -0.26 | -0.10 |
Diluted Net EPS (GAAP) | NA | -0.12 | -0.19 | -0.26 | -0.10 |